Severin Investments LLC Invests $479,000 in Ascendis Pharma A/S $ASND

Severin Investments LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, Holdings Channel.com reports. The fund purchased 2,246 shares of the biotechnology company’s stock, valued at approximately $479,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 68,855 shares of the biotechnology company’s stock worth $14,683,000 after purchasing an additional 807 shares during the period. Clearstead Advisors LLC raised its position in shares of Ascendis Pharma A/S by 227.7% during the 4th quarter. Clearstead Advisors LLC now owns 2,677 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 1,860 shares during the period. Hantz Financial Services Inc. raised its position in shares of Ascendis Pharma A/S by 47.0% during the 4th quarter. Hantz Financial Services Inc. now owns 1,241 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 397 shares during the period. Beck Bode LLC acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $17,291,000. Finally, Legato Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 15.8% during the 4th quarter. Legato Capital Management LLC now owns 2,023 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 276 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ASND shares. The Goldman Sachs Group reiterated a “buy” rating and set a $255.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Oppenheimer increased their price objective on Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Citigroup started coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Bank of America increased their price objective on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $295.39.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $235.26 on Thursday. The stock has a fifty day moving average price of $233.40 and a two-hundred day moving average price of $222.79. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The firm has a market cap of $14.68 billion, a P/E ratio of 27.13 and a beta of 0.41. Ascendis Pharma A/S has a 1 year low of $156.56 and a 1 year high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Research analysts forecast that Ascendis Pharma A/S will post 11.73 EPS for the current fiscal year.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jean Jacques Bienaime acquired 400 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, May 26th. The shares were bought at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the purchase, the director owned 400 shares in the company, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.